Other · developed by Skye Bioscience
Nimacimab is an investigational agent studied in obesity.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06577090 | Phase 2 | Obesity | Active not recruiting | SKYE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Obesity
Updated Nov 1, 2026. Something wrong or missing? Report it on the SKYE page.
See SKYE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SKYE catalysts and pipeline →